SOURCE: Protherics PLC

November 29, 2007 12:33 ET

Protherics PLC announces Application for Listing

Cheshire, UK--(Marketwire - November 29, 2007) -

                                 Protherics PLC

                            Application for Listing

London, UK; Brentwood, TN, US: 29 November - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that today, application has been made to the UK Listing Authority and the London Stock Exchange for 253,211 ordinary shares of 2p each in the Company (the "Shares") to be admitted to trading on the Official List and to trading on London Stock Exchange's main market. The Shares have been allotted pursuant to the conversion of EUR300,000 in nominal value of convertible loan notes (the "Notes") issued to CoVaccine BV on 2 November 2007.

The Notes were received under the terms of an agreement entered into by the Company with CoVaccine BV on 6 June 2006 in respect of the acquisition of CoVaccine's novel adjuvant CoVaccine HT™. Further details are contained in the Company's announcements dated 7 June 2006 and 2 November 2007.

The Shares will rank equally with the existing issued ordinary shares of the Company and are expected to commence trading around 4 December 2007.

Following admission of the Shares, the Company's issued share capital will be 339,950,033 Ordinary Shares.

                                   |  Ends  |

For further information please contact:

 Protherics
 Nick Staples, Director of Corporate Affairs          +44 (0) 7919  480510
 Julie Vickers, Company Secretary                     +44 (0)1928 518010

 Financial Dynamics - press enquiries
 London: Ben Atwell, Lara Mott                        +44 (0) 20 7831 3113
 New York: John Capodanno, Jonathan Birt              +1 212 850 5600
Or visit www.protherics.com

                      This information is provided by RNS
            The company news service from the London Stock Exchange